Pacific Biosciences of California Inc (Pacific Biosciences) designs, develops, and manufactures sequencing systems to solve complex genetic abnormalities. The company reports its operations under a single segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on creating and improving platforms, while also striving to enhance efficiency and reduce costs for its clients. The company is currently developing higher throughput platforms that utilize its HiFi long-read sequencing and SBB short-read sequencing technologies. It is also developing a benchtop HiFi platform to improve accessibility for smaller laboratories and continues to extend its on-market platforms, Revio and Onso. The company also innovates across end-to-end workflows to improve usability and develop new applications for the advancement of human health. In addition to platform development, it continuously innovates across end-to-end workflows to improve usability and develop new applications for the advancement of human health. The company also began taking orders and shipping its new Vega benchtop long-read sequencing system in the fourth quarter of 2024. The company carries out its R&D activities at a leased facility in Menlo Park, California, the US. As of December 31, 2024, the company owns or holds exclusive licenses to 448 issued US patents, 69 pending US patent applications, eight pending Patent Cooperation Treaty (PCT) patent applications, 265 issued foreign patents, and 120 pending foreign patent applications. The company also has non-exclusive patent licenses with various third parties. The licensed patents span various technologies, including SMRT nucleic acid sequencing and various methods to analyze ZMW arrays, surface treatments, phospholinked nucleotides, biological samples, other reagents used in nucleic acid sequencing, optical components and systems, processes for analysis and comparison of nucleic acid sequence data, and processes for identifying nucleotides in nucleic acid sequences. In FY2024, the company spent US$134.9 million on its R&D activities, which as a percentage of revenue stood at 87.5%. As of December 31, 2024, the company had 207 employees working in its R&D division.